Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SD/01 pegfilgrastim: Phase II data; Phase III

In a Phase II trial of 152 breast cancer patients, a single

Read the full 128 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE